Ultragenyx Pharmaceutical | RARE

Ultragenyx Pharmaceutical traded at $62.65 this Friday July 1st, increasing $2.99 or 5.01 percent since the previous trading session. Looking back, over the last four weeks, Ultragenyx Pharmaceutical gained 25.40 percent. Over the last 12 months, its price fell by 33.50 percent. Looking ahead, we forecast Ultragenyx Pharmaceutical to be priced at 60.95 by the end of this quarter and at 56.13 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Kyowa Hakko Kirin 3,115.00 35.00 1.14% -21.93%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Aptinyx Inc 0.55 -0.01 -1.42% -80.50%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Epizyme 1.48 0.01 0.68% -81.41%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Insmed 20.89 1.17 5.93% -26.70%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
MacroGenics 3.05 0.10 3.39% -89.37%
Moderna Inc 149.95 7.10 4.97% -36.00%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%
Immunic Inc. 3.47 0 0% -73.89%
Xoma 20.84 -1.44 -6.46% -37.42%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.